Overview
Progress in the Reversal of DOACs in Emergent Medical Situations
DOAC Reversal Update
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In this activity, a three-faculty panel of experts discuss clinical situations with emergent needs for direct oral anticoagulant (DOAC) reversal. Faculty are featured via a video-recorded conference, complete with an accompanying PowerPoint presentation. This virtual forum provides an objective, non-judgmental review of adverse DOAC outcomes and systematic process changes regarding situations where DOAC reversal should be applied.
The activity is intended for hospitalists, cardiologists, primary care physicians, nurses and other clinicians who manage anticoagulation.
Clinicians require comprehensive knowledge of available and emerging DOAC reversal agents to appropriately apply them in emergent clinical situations. The goal for this activity is to guide clinical decisions, ranging from application of reversal approaches to resumption of DOAC therapy and timing after a patient experiences bleeding or thromboembolism.
Upon completion of this activity, participants will be able to:
- Outline current approaches and challenges to management of bleeding in patients receiving DOACs
- Compare and contrast available and emerging reversal agents for DOACs, including their mechanisms of action and available data
- Discuss approaches to DOAC reversal across diverse patient populations
- Outline current approaches and challenges to management of bleeding in patients receiving DOACs
- Compare and contrast available and emerging reversal agents for DOACs, including their mechanisms of action and available data
- Discuss approaches to DOAC reversal across diverse patient populations
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from Portola Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Christian T. Ruff, MD, MPH (Chair/Moderator)
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
Assistant Professor of Medicine, Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Boston, MA
Elaine Hylek, MD, MPH
Professor of Medicine, Boston University School of Medicine
Medical Director - Thrombosis Clinic and Anticoagulation Service, Boston Medical Center
Boston, MA
Bryan Kluck, DO
Cardiologist
Lehigh Valley Health Network
Allentown, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Elaine Hylek, MD, MPH
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo, Janssen
Bryan Kluck, DO
Speakers Bureau: Janssen Pharmaceuticals, Boehringer Ingelheim GmbH
The following financial relationships have been provided:
Christian T. Ruff, MD, MPH
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo, Portola Pharmaceuticals, Inc., Janssen
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo, Portola Pharmaceuticals, Inc., Janssen
Pharmaceuticals
Grants/Research Support: Daiichi Sankyo
Elaine Hylek, MD, MPH
Consultant: Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Daiichi Sankyo, Janssen
Pharmaceuticals, Medtronic, Pfizer Inc., Portola Pharmaceuticals, Inc.
Scientific Symposia: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., DOASENSE GmbH, Pfizer Inc.
Bryan Kluck, DO
Speakers Bureau: Janssen Pharmaceuticals, Boehringer Ingelheim GmbH
Discussion of Off-Label, Investigational, or Experimental Drug Use: Agents under investigation for reversal
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.